News for NOVN Stock

Ligand Offers $15 Million to Acquire Assets of Novan, Inc. Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders Novan Focuses Strategic Direction and Announces Restructuring Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update Novan to Report First Quarter 2023 Financial Results on May 15, 2023 Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹ Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD Novan Reports Full Year 2022 Financial Results and Provides Corporate Update Novan to Report Full Year 2022 Financial Results on March 30, 2023 Novan Announces Closing of $6.0 Million Registered Direct Offering Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference Novan Announces $6.0 Million Registered Direct Offering Novan Moves Forward with Unified Corporate Branding FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024 Novan to Present at the Virtual Investor 2023 Companies to Watch Event Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE® in Japan EPI Health, a Novan Company, Executes a $15.0 Million Financing Agreement Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update Novan to Report Third Quarter 2022 Financial Results on November 14, 2022 EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA’s® Unique PAD Technology™ at the 42nd Annual Fall Clinical Dermatology Conference® EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall Clinical Dermatology Conference® Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference® EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% Subgroup Data Analysis at Skin of Color Update 2022 Conference Novan Reports Second Quarter 2022 Financial Results and Provides Corporate Update Novan to Report Second Quarter 2022 Financial Results on August 11, 2022 Novan Satisfies $16.5 Million Outstanding Promissory Note Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (SB206) in Patients with Molluscum Contagiosum in JAMA Dermatology Novan Announces Closing of Approximately $15.0 Million Registered Direct Offering Priced At-the-Market Novan Announces Approximately $15.0 Million Registered Direct Offering Priced At-the-Market Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology Novan Reports First Quarter 2022 Financial Results and Provides Corporate Update Novan to Report First Quarter 2022 Financial Results on May 16, 2022 Novan to Participate in the Virtual Investor Innovation in Dermatology Spotlight Event Novan Announces Late-Breaking Abstract Accepted for Presentation at American Academy of Dermatology’s (AAD) 2022 Annual Meeting Novan, Inc. to Present at Two Upcoming Investor Conferences EVENING POST GROUP SELLS EPI HEALTH TO NOVAN, INC Novan Acquires EPI Health, a Specialty Dermatology Company Novan Reports Full Year 2021 Financial Results and Provides Corporate Update Novan to Report Full Year 2021 Financial Results on February 22, 2022 Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology Conference Novan to Participate in the Virtual Investor Roundtable Event Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results Novan Announces Favorable Preclinical Safety Data and Intent to Advance SB019 for Treatment of COVID-19 Novan Announces Fireside Chat Hosted by Jonathan Aschoff, Ph.D. of ROTH Capital Partners Novan to Report Third Quarter 2021 Financial Results on November 10, 2021 Novan Appoints Brian M. Johnson as Chief Commercial Officer and Receives Conditional FDA Acceptance of Proposed Brand Name KINSOLUS™ for SB206 in Molluscum Contagiosum Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206 Novan to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference Novan Announces Strategic Priorities and Outlines Key Milestones Novan Engages Syneos Health as Commercial Solutions Provider for SB206 Novan to Present at H.C. Wainwright 23rd Annual Global Investment Conference Novan to Host Corporate Update Conference Call and Webcast on September 9, 2021 Novan Appoints Tomoko Maeda-Chubachi, MD, PhD, MBA as Chief Medical Officer Novan Reports Second Quarter 2021 Financial Results and Provides Corporate Update Novan to Report Second Quarter 2021 Financial Results on August 12, 2021 Novan Announces Last Patient Visit at Week 24 in B-SIMPLE4 Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum Novan Announces Inclusion in Russell Microcap® Index Novan Announces Closing of $40 Million Public Offering of Common Stock Novan Announces Pricing of $40 Million Public Offering of Common Stock Novan Announces Proposed Public Offering of Common Stock Novan Reports Positive Topline Results from Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum Novan Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program Results from Novan’s Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health Novan Announces 1-for-10 Reverse Stock Split Novan Reports First Quarter 2021 Financial Results and Provides Corporate Update Novan Announces Final Week-12 Visit for Last Patient in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology Novan to Present at the H.C. Wainwright Global Life Sciences Conference Novan Bolsters Commercialization Expertise with Election of Steven D. Skolsky to Board of Directors Novan Reports Full Year 2020 Financial Results and Provides Corporate Update Novan Completes Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum Novan Regains Compliance with Nasdaq Minimum Bid Price Requirement Novan Provides Enrollment Update and Announces New Corporate Headquarters Novan to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference Novan Engages Catalent to Develop Intranasal Formulation of Berdazimer Sodium for COVID-19 Program Novan Exceeds 60% Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum Novan Receives Approval to Transfer to Nasdaq Capital Market Novan Reports Third Quarter 2020 Financial Results and Provides Corporate Update Novan to Present at the Virtual Investor KOL Roundtable Novan’s NITRICIL™ Technology Shows In Vitro Antiviral Effect Against SARS-CoV-2 in Human Airway Infection Model Novan Strengthens Financial Leadership with Appointments of Chief Financial Officer and Seasoned Industry Executive to Board of Directors Novan Provides Pipeline and Priority Development Programs Update Novan to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Novan Announces First Patient Enrolled and Dosed in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum Novan Initiates B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum Novan Anticipates Current Cash Position Provides Sufficient Capital to Conduct Additional SB206 Phase 3 Pivotal Trial Novan Announces Receipt of Written Minutes from Type C Meeting with FDA Regarding Development of SB206 Novan to Host Live Audio Webcast of 2020 Annual Meeting of Stockholders Novan to Present at Virtual Life Sciences Investor Forum on June 25 Novan President and CEO, Paula Brown Stafford Named Chairman of the Board